Aeterna Zentaris Inc. formed a special board committee to review strategic options.

The review process may result in different outcomes or no outcome, the company noted. In addition, there is no guarantee that the company will pursue or execute transactions.

Macrilen, or macimorelin, is the company's medicine approved for diagnosing adult growth hormone deficiency in the EU and U.S. Adult growth hormone deficiency, or AGHD, occurs when the body's anterior pituitary gland does not produce enough growth hormone.

Summerville, S.C.-based Aeterna Zentaris is engaged in developing pharmaceutical products that address unmet medical needs of patients with rare endocrine diseases.

Torreya is acting as the company's financial adviser in the strategic review.